Tailoring Rituximab according to memory B-cell vs B-cell monitoring in Neuromyelitis Optica Spectrum Disorder and MOGAD

被引：0
|
作者：
Bruschi, N. [1 ]
机构：
[1] Azienda Osped Univ San Luigi Gonzaga, Ctr Riferimento Reg SM, 3 AUO S Luigi, Orbassano, Italy
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2022年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO-402
引用
收藏
页码：636 / 636
页数：1
相关论文
共 50 条
  • [1] B-cell depletion therapy using rituximab in neuromyelitis optica spectrum disorders
    Kim, H. J.
    Kim, W.
    Park, M. S.
    Ha, C. K.
    Jung, I. J.
    Lee, K. I.
    [J]. MULTIPLE SCLEROSIS, 2009, 15 (09): : S253 - S254
  • [2] A paraneoplastic neuromyelitis optica spectrum disorder associated with a mature B-cell neoplasm
    Nakayama-Ichiyama, Shoko
    Yokote, Taiji
    Hiraoka, Nobuya
    Iwaki, Kazuki
    Takayama, Ayami
    Kobayashi, Kichinosuke
    Akioka, Toshikazu
    Oka, Satoko
    Miyoshi, Takuji
    Takubo, Takayuki
    Tsuji, Motomu
    Hanafusa, Toshiaki
    [J]. LEUKEMIA RESEARCH, 2011, 35 (07) : E111 - E113
  • [3] Tailoring Rituximab According to CD27-Positive B-Cell versus CD19-Positive B-Cell Monitoring in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: Results from a Single-Center Study
    Bruschi, Nicolo
    Malentacchi, Maria
    Malucchi, Simona
    Sperli, Francesca
    Martire, Serena
    Sala, Arianna
    Valentino, Paola
    Bertolotto, Antonio
    Pautasso, Marisa
    Capobianco, Marco Alfonso
    [J]. NEUROLOGY AND THERAPY, 2023, 12 (04) : 1375 - 1383
  • [4] Tailoring Rituximab According to CD27-Positive B-Cell versus CD19-Positive B-Cell Monitoring in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: Results from a Single-Center Study
    Nicolò Bruschi
    Maria Malentacchi
    Simona Malucchi
    Francesca Sperli
    Serena Martire
    Arianna Sala
    Paola Valentino
    Antonio Bertolotto
    Marisa Pautasso
    Marco Alfonso Capobianco
    [J]. Neurology and Therapy, 2023, 12 : 1375 - 1383
  • [5] Intravascular Large B-cell Lymphoma Presenting as Seronegative Neuromyelitis Optica Spectrum Disorder
    Kanokkawinwong, N.
    Jitprapaikulsan, J.
    Prayoonwiwat, N.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (02) : 355 - 355
  • [6] Prolonged B-cell depletion after rituximab in AQP4-IgG-positive neuromyelitis optica spectrum disorder
    Sechi, Elia
    Zarbo, Roberto
    Biancu, Maria Angela
    Chessa, Paola
    Idda, Maria Laura
    Orru, Valeria
    Lai, Sandra
    Leoni, Stefania
    Solla, Paolo
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2021, 358
  • [7] Duration of B-cell depletion in patients receiving ocrelizumab or rituximab for Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorders
    AbdelRazek, M. A.
    Casasola, M.
    Mollashahi, R.
    Brodski, A.
    Morin, S.
    Augustynowicz, A.
    Jassim, S.
    Matiello, M.
    Sloane, J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 100 - 100
  • [8] Probiotics-regulated lithocholic acid suppressed B-cell differentiation in neuromyelitis optica spectrum disorder
    Cheng, Xi
    Cui, Chunping
    Shen, Shishi
    Li, Zhibin
    Zhao, Yipeng
    Li, Caixia
    Kermode, Allan G.
    Zhong, Xiaonan
    Qiu, Wei
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2024, 395
  • [9] B Cell Therapies in Neuromyelitis Optica Spectrum Disorder
    Kim, Ho Jin
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (02) : 308 - 308
  • [10] Correlation of B-cell depletion and disease activity after treatment with rituximab in patients with neuromyelitis optica
    Pellkofer, H. L.
    Hohlfeld, R.
    Kuempfel, T.
    [J]. MULTIPLE SCLEROSIS, 2009, 15 (09): : S130 - S131
12345